1. Introduction {#s0005}
===============

Bipolar disorder (BD) patients suffer from multiple functional impairments including impoverished social functioning ([@bb0050], [@bb0330]), which have prompted investigations into social-cognitive deficits in BD. Social cognition is a multidimensional construct that includes identifying affect others display, inferring others\' mental states, attributing meanings to others\' actions, reading others\' social cues, applying a working knowledge of social rules to socially reciprocate in kind, and managing one\'s own emotional responses to maintain interpersonal relationships ([@bb0160], [@bb0150], [@bb0325]). Understanding bipolar patients\' social-cognitive deficits may help illuminate mechanisms underlying impaired social competence in BD, which may help inform interventions to improve psychosocial functioning.

Yet to date, results of social cognition studies in BD have been inconsistent. While some studies have found social-cognitive deficits ([@bb0030], [@bb0035], [@bb0070], [@bb0170], [@bb0185], [@bb0205], [@bb0230], [@bb0250], [@bb0280], [@bb0275], [@bb0370], [@bb0375], [@bb0445]), others have found mixed results with preserved aspects alongside deficits ([@bb0010], [@bb0130], [@bb0295], [@bb0300], [@bb0310], [@bb0345], [@bb0355], [@bb0390], [@bb0430]), and others have found no deficits relative to controls ([@bb0015], [@bb0245], [@bb0420], [@bb0425], [@bb0435]). Social-cognitive differences have also been found between BD−I and BD−II, or between manic or depressive phases of BD ([@bb0080], [@bb0140]). As a result, the nature of social-cognitive deficits in BD remains inconclusive.

In contrast, schizophrenia spectrum disorders (SSD) have consistently shown substantial deficits in both social cognition and neurocognition ([@bb0060], [@bb0075], [@bb0100], [@bb0120], [@bb0145], [@bb0210], [@bb0220], [@bb0240], [@bb0405], [@bb0410], [@bb0415]). Findings suggest that such deficits remain stable across phases of psychosis ([@bb0145]) and are linked to SSD patients\' quality of life and community, work, and social functioning ([@bb0120], [@bb0190], [@bb0210], [@bb0265], [@bb0360], [@bb0365], [@bb0415]). Moreover, results suggest that social cognition is more strongly linked with community functioning than neurocognition ([@bb0105]), and mediates the relationship between neurocognition and functional outcomes ([@bb0020], [@bb0350]).

Recently, it has been suggested that inconsistent past findings in BD may reflect the impact of co-occurring psychotic symptoms on social-cognitive performance ([@bb0395], [@bb0400]), especially considering \~ 60% of bipolar patients will also experience psychotic symptoms at some point during their lifetimes ([@bb0090]). Specifically, bipolar patients with psychotic features (BD +) have shown greater social-cognitive deficits than those without psychotic features (BD −) ([@bb0395], [@bb0400]). Although we previously reported ([@bb0045]) no significant effect of a history of psychotic features in a bipolar sample substantially overlapping with the sample used in our current analyses, our prior work did not control for neurocognition and did not directly compare against SSD, which may have limited these past findings. In addition, although a study by [@bb0245] also found no effect of a history of psychotic features on their BD patients\' social-cognitive deficits, only 15 of their 68 patients (\~ 22%) had a history of psychotic features, and thus this sample may have been underpowered to detect group differences. Therefore, it is possible that social-cognitive deficits may present in BD + but not BD − when directly compared to SSD and controls.

Examining social cognition across SSD, BD +, BD −, and controls may illuminate whether a history of psychotic features impairs social cognition in BD relative to SSD. Findings could help identify BD patients in need of social-cognitive interventions and help elucidate if social cognition represents an underlying difference between BD and SSD. Thus, we compared social-cognitive performance differences among these diagnoses while controlling for neurocognition and psychotropic medication status.

2. Methods {#s0010}
==========

2.1. Participants {#s0025}
-----------------

Our sample consisted of 968 participants, with 537 SSD patients (447 schizophrenia and 90 schizoaffective disorder patients), 85 BD + patients, 37 BD − patients, and 309 controls. For full demographics and clinical characteristics, see [Table 1](#t0005){ref-type="table"}. All participants gave written informed consent to protocols approved by the Institutional Review Board of the North Shore-Long Island Jewish Health System (NSLIJ). Controls were recruited using newspaper and Internet advertisements, posted flyers, and personal referrals. Patients were referred from the outpatient and inpatient psychiatric departments of Zucker Hillside Hospital (ZHH), part of NSLIJ. Controls were excluded if diagnosed with past or present Axis-I disorders, had substance abuse within the past month, or had a history of learning disability, neurological disorder, or CNS trauma. Patients were excluded if they had a history of learning disability, neurological disorder, or CNS trauma.Table 1Study group and subsample demographics and clinical characteristics.Healthy controlBipolar disorder (BD) without psychotic featuresBipolar disorder (BD) with Psychotic featuresSSD spectrum disorderStatistic*p*Total sample *N*3093785537--BD 1 (*N* = 17)BD 2 (*N* = 20)BD 1 (*N* = 85)BD 2 (*N* = 0)------Age: mean (SD)40.52 (16.34)41.24 (10.06)40.61 (11.43)43.26 (10.20)*F*(3,967) = 3.62*p* \< .05% Female55.99%59.46%\`55.29%26.82%*χ*^2^(3,967) = 86.01*p* \< .001% Caucasian52.75%54.05%56.47%37.80%*χ*^2^(6,967) = 39.85*p* \< .001Substance disorder history0%16.22%27.05%40.22%----Anticonvulsant use01832186----Antidepressant use01519161----Mood stabilizer use0112140----Antiparkinsonian use0410139----Anxiolytic use05856----Antipsychotic use02354461----Sedative/Hypnotic use04626----Stimulant use0106----  *N* of subsample with BPRS--2160492------BD 1 (*N* = 11)BD 2 (*N* = 10)BD 1 (*N* = 60)BD 2 (*N* = 0)------Brief psychiatric rating\
scale (BPRS): Mean (SD)------------Thinking Disturbance--3.86 (1.11)4.23 (2.04)6.16 (3.04)*F*(2,572) = 17.15*p* \< .001Withdrawal/Retardation--3.05 (1.07)2.75 (1.28)3.66 (1.86)*F*(2,572) = 7.86*p* \< .001Hostile/Suspiciousness--4.86 (1.68)4.45 (1.78)4.99 (2.06)*F*(2,572) = 1.92nsAnxious/Depression--6.48 (2.89)5.02 (2.40)4.85 (2.22)*F*(2,572) = 5.22*p* \< .01Activation--4.86 (2.01)4.47 (1.92)4.47 (1.86)*F*(2,572) = 0.43nsBPRS Total Score--29.10 (5.80)27.07 (7.58)31.14 (7.44)*F*(2,572) = 8.58*p* \< .001

2.2. Clinical assessments {#s0030}
-------------------------

### 2.2.1. Diagnostic assessment {#s0035}

Controls were administered the Structured Clinical Interview for the DSM-IV, non-patient edition (SCID-I/NP; [@bb0110]) and patients were administered the patient edition (SCID-I/P; [@bb0115]) by Ph.D. or Master\'s level psychometricians. Controls\' SCIDs were compiled into narrative case summaries and no Axis-I pathology was determined by consensus of two senior ZHH faculty. Patients\' SCIDs were supplemented by available records and compiled into narrative case summaries and diagnoses were determined by consensus of three senior ZHH faculty.

2.3. Symptom assessment {#s0040}
-----------------------

Patients\' clinical symptoms were assessed by trained Master\'s level psychometricians using the *Brief Psychiatric Rating Scale* (BPRS; [@bb0315]), a semi-structured clinical interview assessing 18 symptoms within the past week.

2.4. Cognitive assessment {#s0045}
-------------------------

To assess neurocognition, all participants were administered the MATRICS Consensus Cognitive Battery (MCCB), which consists of 10 measures assessing seven domains: (1) processing speed, measured by the symbol coding subtest of the *Brief Assessment of Cognition in Schizophrenia* (BACS symbol coding; [@bb0215]), the *Trail Making Test: Part A* (Trails-A; [@bb0005]), and *Category Fluency: Animal Naming* (animal naming; [@bb0380]); (2) attention/vigilance, measured by the *Continuous Performance Test---Identical Pairs* (CPT-IP; [@bb0065]); (3) working memory, measured by the spatial span subtest of the *Wechsler Memory Scale, Third Edition* (WMS-III spatial span; [@bb0440]) and *Letter--Number Span* (LNS; [@bb0135]); (4) verbal learning, measured by the *Hopkins Verbal Learning Test---Revised* (HVLT-R; [@bb0040]); (5) visual learning, measured by the *Brief Visuospatial Memory Test---Revised* (BVMT-R; [@bb0025]); (6) reasoning and problem solving, measured by the *Neuropsychological Assessment Battery* mazes subtest (NAB Mazes; [@bb0385]); and (7) social cognition, measured by the managing emotions branch of the *Mayer--Salovey Emotional Intelligence Test* (MSCEIT; [@bb0285]).

The MSCEIT has evidenced robust psychometric properties, with demonstrated applicability in BD ([@bb0045], [@bb0245]), SSD ([@bb0165]), and controls ([@bb0225]), good internal consistency ([@bb0100], [@bb0290]), good sensitivity to deficits in SSD and BD ([@bb0045], [@bb0210], [@bb0420]), and good validity in SSD, as SSD patients\' MSCEIT performance has been significantly linked to social functioning ([@bb0360]) and residential independence ([@bb0255]), and has been improved by social-cognitive interventions ([@bb0095]).

2.5. MCCB scoring {#s0050}
-----------------

While published norms were available for each MCCB domain ([@bb0225]), our sample of healthy control participants was better demographically matched to our bipolar and schizophrenia spectrum patient samples, as the [@bb0225] data were not stratified by race. Specifically, the [@bb0225] healthy control sample consisted of 76% Caucasian participants, whereas our healthy control participants consisted of 52.75% Caucasian participants, which was better matched to our BD −, BD +, and SSD patients (being 54.05%, 56.47% and 37.8% Caucasian, respectively). Thus, we chose to calculate Z-scores using means and standard deviations derived from our healthy control data, which provided improved demographic matching on race. Using our healthy control data, age and sex were regressed out of each MCCB raw score to produce standardized residuals that were then transformed to Z-scores. A neurocognition score was calculated by averaging across the 6 nonsocial MCCB domains. Next, MSCEIT and neurocognition Z-scores were inspected for outliers over ± 3 standard deviations from the mean. There were no outliers for neurocognition, but 4 extreme low MSCEIT scores were identified and excluded (i.e. one BD +, two SSD, and one control case). Resulting age- and sex-corrected Z-scores consisted of (1) an MSCEIT Z-score and (2) a neurocognition Z-score. Both were normally distributed (K--S = 0.83 and 1.16 for neurocognition and MSCEIT, respectively, both *p*\'s \> 0.05). Since we chose to derive MCCB scores using our own healthy control data, we have provided T-score means and standard deviations for all our diagnostic groups using the MCCB published norms in [Table 2](#t0010){ref-type="table"} for descriptive purposes and for ease of comparison to previous work on the MCCB.Table 2MCCB domain scores by diagnostic group standardized using MCCB normative data.MCCB domainHealthy control (*N* = 309)Bipolar disorder without psychotic features (*N* = 37)Bipolar disorder with psychotic features (*N* = 85)SSD spectrum disorder (*N* = 537)Mean (SD)Mean (SD)Mean (SD)Mean (SD)Processing speed48.63 (10.43)40.19 (10.69)38.12 (9.05)29.80 (14.03)Attention vigilance46.97 (10.66)39.76 (12.91)36.89 (12.86)32.13 (12.36)Working memory44.82 (10.44)37.57 (13.04)37.47 (10.51)31.76 (13.16)Verbal learning42.59 (8.28)39.38 (8.96)37.76 (7.29)34.50 (7.36)Visual learning41.57 (11.74)34.84 (12.27)35.80 (12.46)30.31 (12.23)Reasoning/problem solving45.68 (10.38)42.22 (8.72)41.01 (8.75)37.49 (8.33)Social cognition49.06 (10.98)47.46 (11.34)44.08 (13.50)35.67 (12.05)Overall composite score42.68 (10.68)34.00 (11.60)31.67 (11.35)22.55 (12.13)

2.6. Data analysis {#s0055}
------------------

Diagnostic groups were first compared on demographics using chi-squares for sex and race and analysis of variance for age. Demographic variables that significantly differed between groups were corrected for or included as covariates.

To investigate whether MSCEIT deficits would be demonstrated in all BD patients relative to SSD and controls, we first compared SSD patients, all BD patients, and controls using analysis of covariance (ANCOVA) controlling for race, neurocognition, and psychotropic medication status. Next, to examine the impact of psychosis history on MSCEIT performance in BD, we conducted a follow-up ANCOVA comparing SSD, BD +, BD −, and control groups, controlling for race, neurocognition, and psychotropic medication status.

Race consisted of a categorical variable with Caucasian, African-American, and other minority group. Psychotropic medication status consisted of 8 dummy-coded variables that each assessed the presence or absence of anticonvulsant, antidepressant, mood stabilizer, antiparkinsonian, anxiolytic, antipsychotic, sedative, or stimulant use. All patients were on at least one form of psychotropic medication and thus all 8 variables were included in all ANCOVAs. No controls had any history of psychotropic medication use.

3. Results {#s0015}
==========

Preliminary analyses revealed the sex and race distributions significantly differed between diagnostic categories, with fewer females and more minorities in the SSD group compared to other groups (sex: *χ*^2^(3,967) = 86.01, *p* \< 0.001; race: *χ*^2^(6,967) = 39.85, *p* \< 0.001). Age also significantly differed between groups, with SSD patients slightly older than controls but no significant age differences between any other groups (*F* (3,967) = 3.62, *p* \< 0.05). Thus, we corrected all MCCB subtests for age and sex and controlled for race in all ANCOVAs.

Results from the first ANCOVA found significant MSCEIT differences between SSD patients, all BD patients, and controls (*F* (2, 964) = 24.85, *p* \< 0.001), controlling for race, neurocognition, and psychotropic medication status. Follow-up pairwise comparisons using Fisher\'s LSD found no significant MSCEIT differences between BD patients and controls, but rather only significant differences between SSD patients and controls and between BD and SSD patients. Significant covariates included neurocognition (*F* (1,964) = 92.29, *p* \< 0.001) and antidepressant use (*F* (1,964) = 11.59, *p* \< 0.001), while all other covariates were non-significant (all *p*\'s \> 0.05).

Results from the second ANCOVA also found significant MSCEIT differences between the BD +, BD −, SSD, and control groups (*F* (3,964) = 16.83, *p* \< 0.001), controlling for race, neurocognition, and psychotropic medication status. Follow-up pairwise comparisons using Fisher\'s LSD found no significant MSCEIT differences between BD +, BD −, and controls. Rather, the only significant difference was between SSD and all other groups. Significant covariates similarly included neurocognition (*F* (1,964) = 91.99, *p* \< 0.001) and antidepressant use (*F* (1,964) = 11.02, *p* \< 0.001), while all other covariates were non-significant (all *p*\'s \> 0.05). For a plot of MSCEIT means across all four diagnostic groups, see [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Social cognition performance across diagnostic categories. *Note*: Error bars represent ± 1 standard error. MSCEIT = the managing emotions branch of the Mayer--Salovey--Caruso Emotional Intelligence Test, the social cognition measure of the MATRICS Consensus Cognitive Battery (MCCB). All MCCB scores including the MSCEIT are age- and sex-corrected, and the comparison of MSCEIT performance across diagnostic groupings controlled for race and neurocognition.

4. Discussion {#s0020}
=============

This study\'s primary aim was to examine social cognition across SSD, BD +, and BD − patients relative to controls. In particular, given \~ 60% of BD patients also experience psychotic symptoms at some point during their lifetimes, often during acute phases of illness ([@bb0090]), and recent studies have found BD + patients to show significant social-cognitive deficits ([@bb0395], [@bb0400]), our study aimed to elucidate whether BD + patients would show impaired MSCEIT performance relative to BD − patients and controls, as well as whether deficits would be consistent with SSD patients. However, in contrast to recent studies showing social-cognitive deficits in BD + ([@bb0395], [@bb0400]), but consistent with past work showing no social-cognitive deficits in BD ([@bb0015], [@bb0245], [@bb0425], [@bb0435]), our analyses found significant MSCEIT deficits in SSD but not BD + or BD − patients relative to controls. These results suggest that social cognition may represent a key underlying difference between SSD and BD.

Another possible explanation is that social-cognitive impairments of BD patients are more heterogeneous than those found in SSD. Consistent with this, our sample of BD + and BD − patients both had larger estimates of standard error on the MSCEIT than the other diagnostic groups, which might indicate the presence of latent bipolar subgroups that differ in their social-cognitive performance. To investigate this possibility, we examined a histogram of MSCEIT Z-scores for easily visible subgroups within our bipolar sample (both BD + and BD −). The distribution was unimodal and normally distributed (K--S = 0.83, *p* \> 0.05), which was not suggestive of latent bipolar subgroups. It is still possible that there are latent subgroups of BD patients with different levels of social-cognitive performance, but that properly identifying these subgroups requires the use of more advanced statistical techniques such as hierarchical cluster analysis. Although outside the scope of the present study, future studies should use larger bipolar cohorts and more sophisticated analytic methods to investigate this possibility of latent subgroups of bipolar patients with differential social-cognitive performance.

An important limitation of our study was the lack of multiple measures of social cognition and the limited scope of the MSCEIT as social cognition measure. Specifically, the MSCEIT has evidenced some weaknesses in its ability to fully tap into the multifaceted construct of social cognition ([@bb0045]), and [@bb0245] used a battery that included multiple aspects of social cognition. Unfortunately, multiple social-cognitive measures were not available for our study. However, one benefit of the MSCEIT is that it is particularly well-suited to our study\'s transdiagnostic focus. Ceiling effects are a key problem for many social-cognitive measures, with controls often performing at over 90% accuracy ([@bb0085]). As a result, past studies may have lacked sensitivity to subtle social-cognitive differences between BD patients and controls. In addition, the factor structure of social cognition in populations suffering from psychotic symptoms is still largely unknown and many measures have inadequate psychometric properties ([@bb0160]). In contrast, the MSCEIT was both developed for non-clinical populations and was the chosen consensus metric of the MCCB for studying serious psychiatric disorders ([@bb0225], [@bb0305]), Thus, while limited in scope, the MSCEIT is apt for studying social-cognitive deficits across SSD and BD subtypes and for verifying past evidence of social-cognitive deficits in BD + patients ([@bb0245], [@bb0395], [@bb0400]). Nevertheless, social cognition remains a multifaceted construct that is not yet fully understood, and it is possible that BD patients may show deficits in social-cognitive domains not fully captured by the MSCEIT. Future studies are needed to develop and validate standardized, multifaceted social-cognitive batteries sensitive to subtle differences across clinical and nonclinical populations. Large-scale studies are also needed to assess performance on these batteries across all SSD and BD subtypes.

Our findings were also limited by differences in demographic distributions between study groups. Specifically, our SSD group was slightly older and had fewer females and more minorities compared to our other groups. However, we controlled for race in all analyses and MCCB subtests were all age- and sex-corrected, which helped attenuate any demographic differences between groups.

Although it may be argued that differences in symptom severity of our patient groups contributed to our findings, we ran a follow-up ANCOVA controlling for the total symptom severity score of the BPRS in a subsample of 570 patients who had been administered the BPRS (i.e., 21 BD −, 59 BD +, and 490 SSD patients). Results confirmed our findings, with no significant MSCEIT deficits in BD − or BD + but significant deficits in SSD relative to controls. Nevertheless, BPRS ratings were unfortunately not available for every patient and thus the possibility clinical symptoms impacted our findings cannot be completely ruled out. Moreover, differences in symptoms are often accompanied by differences in medication status. However, our analyses controlled for 8 classes of psychotropic medications and although including these 8 covariates had the potential to adversely affect statistical power, our large sample size withstood the inclusion of these covariates while maintaining excellent power (1 − *β* = 0.9).

In summary, our evidence supports past work showing social-cognitive deficits in SSD but not BD + or BD − relative to controls ([@bb0015], [@bb0245], [@bb0425], [@bb0435]). While these data suggest that social cognition may represent an underlying difference between SSD and BD, the large variance in social-cognitive performance among the bipolar groups is also suggestive of heterogeneity in performance and may indicate a latent bipolar subgroup characterized by social-cognitive deficits. Results highlight the importance of developing standardized social-cognitive batteries for use across BD and SSD and emphasize the need for future work on social brain development in clinical populations.
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